Mpox Vaccine Contract: Bavarian Nordic Wins $63M from U.S.
Mpox Vaccine Contract Overview
Bavarian Nordic (BVNRY) has secured a $63 million contract from the U.S. government to manufacture critical components for its mpox vaccine, Jynneos. This FDA-approved vaccine is essential for combating mpox and smallpox. The contract signifies a vital step in reinforcing public health measures against these viral threats.
Components of the Contract
- Funding Amount: $63 million
- Vaccine: Jynneos
- Targeted Diseases: Mpox and Smallpox
Implications of the Contract
This contract is pivotal, emphasizing the focus on developing next-generation vaccines. In light of recent health challenges, enhancing vaccine supply chains is crucial for effective public health strategies.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.